Annovis Bio

Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …

Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More
Annovis Bio

Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease

BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …

Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More